Advertisement
Salesforce
Salesforce

Fighting Cancer with Light

Researchers have developed a way to activate cancer fighting drugs by pulsing them with light, which could make such therapies safer.

By | November 7, 2011

Laser used for light-activated cancer therapyWIKIMEDIA COMMONS, NATIONAL CANCER INSTITUTE

Researchers have demonstrated a way to selectively target cancer cells for destruction—light. Researchers from the National Cancer Institute in Maryland used an antibody that targets proteins expressed on cancer cells to target tumors, and tagged it with a chemical that, when hit with a certain wavelength of near infrared light, becomes toxic to cells, according to the paper published Sunday (November 6) in Nature Medicine. By waiting until the antibody had bound to tumor cells before exposing it to infrared radiation, the researchers could effectively target just the cancer, and not the surrounding healthy tissue.

Importantly, the treatment was effective. The tumors of treated mice shrank significantly, with minimal damage to normal cells. Treated mice also lived significantly longer than controls, BBC News reported.

Advertisement

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Comments

Avatar of: Dr. Ichha Purak

Dr. Ichha Purak

Posts: 1457

November 11, 2011

The commbination of chemical and near Infrared light give toxic effects to cancer cells and not surrounding healthy cells indicates right line of action with future prospects in tackling tumors

Avatar of:

Posts: 0

November 11, 2011

The commbination of chemical and near Infrared light give toxic effects to cancer cells and not surrounding healthy cells indicates right line of action with future prospects in tackling tumors

Avatar of:

Posts: 0

November 11, 2011

The commbination of chemical and near Infrared light give toxic effects to cancer cells and not surrounding healthy cells indicates right line of action with future prospects in tackling tumors

Avatar of:

Posts: 0

November 15, 2011

We may well find ourselves gaining much valuable information about specific applications utilizing various bands of the electromagnetic spectrum in ontology in years ahead.  Particular electromagnetic frequencies impact particular pharmaceutical products in specific challenging ways.  Parts of cells respond to particular frequencies in preference to others, even without chemical intervention.  As ontological research increasingly makes inroads into the understanding of mutation system pathways and responses at the molecular level, specific intracellular responses may turn out to be "tunable" in their cellular functions, and attention to specific electromagnetic-electrochemical interplay may well provide means of tighter identification and manipulation of cancer system pathways and precancerous conditions early on. And the result may be that such specific interventions as the selective triggering of apoptosis in particular mutations, and more specific disruption of points in cancer system pathways may be attainable. This could be the way to the treatment protocols of months or years to come.  The days of blunt target disruptions already are giving way to ever finer specific molecular interactions and markers for evaluating treatment results. Fine selective apoptosis triggering protocols may be enabled. Fine selective interruption of cancer system pathways may be enabled. We may learn that increased appreciation of electrolytic and electromagnetic factors in cancer etiology are in order. Beyond some point, bio-physics may be, after all, indistinguishable from any other micro-emergent levels of applied physics.

Avatar of:

Posts: 0

November 15, 2011

Decades ago it was found that die-light therapy, in treating herpes one, could trigger at least one kind of cancer in the vicinity.  If memory serves me well, the die was gentian violet and the light applied to a cold sore to which the die had been applied was in the ultraviolet range.  As a result of the number of cancers occurring in the vicinity of such Rx, following that protocol, it was abandoned.  The treatment did, by the way, arrest the normal progress of the lesion. 

Sometimes serendipity occurs in disguise.  Perhaps now we have sufficient knowledge to go repeat the treatment on laboratory animals and evaluate what normal pathway was less likely to result in development of a cancer at a former lesion site in absence of the treatment, than was more likely to result by whatever normal process tended to be corrupted by the die-light therapy. 

What process can be understood can also be compared and analyzed productively in relation to other sources and kinds of corruptions of normal systems. Of course, that presumes the absence of cancer to be "normal," and the occurrence of a cancer to be "abnormal."  Some of us do prefer to think of it that way.

Avatar of:

Posts: 0

November 15, 2011

We may well find ourselves gaining much valuable information about specific applications utilizing various bands of the electromagnetic spectrum in ontology in years ahead.  Particular electromagnetic frequencies impact particular pharmaceutical products in specific challenging ways.  Parts of cells respond to particular frequencies in preference to others, even without chemical intervention.  As ontological research increasingly makes inroads into the understanding of mutation system pathways and responses at the molecular level, specific intracellular responses may turn out to be "tunable" in their cellular functions, and attention to specific electromagnetic-electrochemical interplay may well provide means of tighter identification and manipulation of cancer system pathways and precancerous conditions early on. And the result may be that such specific interventions as the selective triggering of apoptosis in particular mutations, and more specific disruption of points in cancer system pathways may be attainable. This could be the way to the treatment protocols of months or years to come.  The days of blunt target disruptions already are giving way to ever finer specific molecular interactions and markers for evaluating treatment results. Fine selective apoptosis triggering protocols may be enabled. Fine selective interruption of cancer system pathways may be enabled. We may learn that increased appreciation of electrolytic and electromagnetic factors in cancer etiology are in order. Beyond some point, bio-physics may be, after all, indistinguishable from any other micro-emergent levels of applied physics.

Avatar of:

Posts: 0

November 15, 2011

Decades ago it was found that die-light therapy, in treating herpes one, could trigger at least one kind of cancer in the vicinity.  If memory serves me well, the die was gentian violet and the light applied to a cold sore to which the die had been applied was in the ultraviolet range.  As a result of the number of cancers occurring in the vicinity of such Rx, following that protocol, it was abandoned.  The treatment did, by the way, arrest the normal progress of the lesion. 

Sometimes serendipity occurs in disguise.  Perhaps now we have sufficient knowledge to go repeat the treatment on laboratory animals and evaluate what normal pathway was less likely to result in development of a cancer at a former lesion site in absence of the treatment, than was more likely to result by whatever normal process tended to be corrupted by the die-light therapy. 

What process can be understood can also be compared and analyzed productively in relation to other sources and kinds of corruptions of normal systems. Of course, that presumes the absence of cancer to be "normal," and the occurrence of a cancer to be "abnormal."  Some of us do prefer to think of it that way.

Avatar of: Guest

Anonymous

November 15, 2011

We may well find ourselves gaining much valuable information about specific applications utilizing various bands of the electromagnetic spectrum in ontology in years ahead.  Particular electromagnetic frequencies impact particular pharmaceutical products in specific challenging ways.  Parts of cells respond to particular frequencies in preference to others, even without chemical intervention.  As ontological research increasingly makes inroads into the understanding of mutation system pathways and responses at the molecular level, specific intracellular responses may turn out to be "tunable" in their cellular functions, and attention to specific electromagnetic-electrochemical interplay may well provide means of tighter identification and manipulation of cancer system pathways and precancerous conditions early on. And the result may be that such specific interventions as the selective triggering of apoptosis in particular mutations, and more specific disruption of points in cancer system pathways may be attainable. This could be the way to the treatment protocols of months or years to come.  The days of blunt target disruptions already are giving way to ever finer specific molecular interactions and markers for evaluating treatment results. Fine selective apoptosis triggering protocols may be enabled. Fine selective interruption of cancer system pathways may be enabled. We may learn that increased appreciation of electrolytic and electromagnetic factors in cancer etiology are in order. Beyond some point, bio-physics may be, after all, indistinguishable from any other micro-emergent levels of applied physics.

Avatar of: Guest

Anonymous

November 15, 2011

Decades ago it was found that die-light therapy, in treating herpes one, could trigger at least one kind of cancer in the vicinity.  If memory serves me well, the die was gentian violet and the light applied to a cold sore to which the die had been applied was in the ultraviolet range.  As a result of the number of cancers occurring in the vicinity of such Rx, following that protocol, it was abandoned.  The treatment did, by the way, arrest the normal progress of the lesion. 

Sometimes serendipity occurs in disguise.  Perhaps now we have sufficient knowledge to go repeat the treatment on laboratory animals and evaluate what normal pathway was less likely to result in development of a cancer at a former lesion site in absence of the treatment, than was more likely to result by whatever normal process tended to be corrupted by the die-light therapy. 

What process can be understood can also be compared and analyzed productively in relation to other sources and kinds of corruptions of normal systems. Of course, that presumes the absence of cancer to be "normal," and the occurrence of a cancer to be "abnormal."  Some of us do prefer to think of it that way.

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
Hamamatsu
Hamamatsu
Advertisement
The Scientist
The Scientist
Life Technologies